{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:39:39Z","timestamp":1778542779551,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1038\/nrd1933","type":"journal-article","created":{"date-parts":[[2006,5,9]],"date-time":"2006-05-09T14:52:50Z","timestamp":1147186370000},"page":"17-18","source":"Crossref","is-referenced-by-count":48,"title":["Nelarabine"],"prefix":"10.1038","volume":"5","author":[{"given":"Varsha","family":"Gandhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Bate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFnrd1933_CR1","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1056\/NEJM199808273390907","volume":"339","author":"C-H Pui","year":"1998","unstructured":"Pui, C.-H. & Evans, W. E. Acute lymphoblastic leukemia. N. Engl. J. Med. 339, 605\u2013615 (1998).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd1933_CR2","first-page":"592","volume":"5","author":"WB Parker","year":"2004","unstructured":"Parker, W. B. et al. Purine nucleoside analogues in development for the treatment of cancer. Curr. Opin. Investig. Drugs 5, 592\u2013596 (2004).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"BFnrd1933_CR3","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1182\/blood-2003-01-0317","volume":"102","author":"CO Rodriguez","year":"2003","unstructured":"Rodriguez, C. O. et al. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood 102, 1842\u20131848 (2003).","journal-title":"Blood"},{"key":"BFnrd1933_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0008-6215(00)80531-5","volume":"97","author":"TA Krenitsky","year":"1981","unstructured":"Krenitsky, T. A. et al. An enzymatic synthesis of purine-D-arabinonucleosides. Carbohydr. Res. 97, 139\u2013146 (1981).","journal-title":"Carbohydr. Res."},{"key":"BFnrd1933_CR5","first-page":"3352","volume":"55","author":"CU Lambe","year":"1995","unstructured":"Lambe, C. U. et al. 2-amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 55, 3352\u20133356 (1995).","journal-title":"Cancer Res."},{"key":"BFnrd1933_CR6","first-page":"4937","volume":"59","author":"CO Rodriguez","year":"1999","unstructured":"Rodriguez, C. O. et al. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res. 59, 4937\u20134943 (1999).","journal-title":"Cancer Res."},{"key":"BFnrd1933_CR7","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1200\/JCO.1998.16.11.3607","volume":"16","author":"V Gandhi","year":"1998","unstructured":"Gandhi, V. et al. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J. Clin. Oncol. 16, 3607\u20133715 (1998).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd1933_CR8","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1200\/JCO.2001.19.8.2142","volume":"19","author":"V Gandhi","year":"2001","unstructured":"Gandhi, V. et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics and pharmacodynamics in leukemia cells. J. Clin. Oncol. 19, 2142\u20132152 (2001).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd1933_CR9","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1200\/JCO.2005.03.199","volume":"23","author":"J Kurtzberg","year":"2005","unstructured":"Kurtzberg, J. et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J. Clin. Oncol. 23, 3396\u20133403 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd1933_CR10","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","volume":"23","author":"SL Berg","year":"2005","unstructured":"Berg, S. L. et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J. Clin. Oncol. 23, 3376\u20133382 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd1933_CR11","unstructured":"FDA labelling information [online], < http:\/\/www.fda.gov\/cder\/foi\/label\/2005\/021877lbl.pdf > (2005)."},{"key":"BFnrd1933_CR12","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.4049\/jimmunol.121.5.1726","volume":"121","author":"DA Carson","year":"1978","unstructured":"Carson, D. A. et al. Differential sensitivity of human leukemic T cell lines and B cell lines to growth inhibition by deoxyadenosine. J. Immunol. 121, 1726\u20131731 (1978).","journal-title":"J. Immunol."},{"key":"BFnrd1933_CR13","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood.V61.4.660.660","volume":"61","author":"A Cohen","year":"1983","unstructured":"Cohen, A. et al. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood 61, 660\u2013666 (1983).","journal-title":"Blood"},{"key":"BFnrd1933_CR14","first-page":"1008","volume":"45","author":"DS Shewach","year":"1985","unstructured":"Shewach, D. S. et al. Metabolism and selective cytotoxicity of 9-\u03b2-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res. 45, 1008\u20131014 (1985).","journal-title":"Cancer Res."},{"key":"BFnrd1933_CR15","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1172\/JCI111514","volume":"74","author":"B Ullman","year":"1984","unstructured":"Ullman, B. & Martin, D. W. J. Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts. J. Clin. Invest. 74, 951\u2013955 (1984).","journal-title":"J. Clin. Invest."},{"key":"BFnrd1933_CR16","first-page":"6498","volume":"49","author":"DS Shewach","year":"1989","unstructured":"Shewach, D. S. & Mitchell, B. S. Differential metabolism of 9-\u03b2-D-arabinofuranosylguanine in human leukemic cells. Cancer Res. 49, 6498\u20136502 (1989).","journal-title":"Cancer Res."},{"key":"BFnrd1933_CR17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1200\/JCO.2000.18.5.995","volume":"18","author":"DF Kisor","year":"2000","unstructured":"Kisor, D. F. et al. The pharmacokinetics of 506U78 and ara-G in pediatric and adult patients during a Phase I study of 506U78 for the treatment of refractory hemato-logic malignancies. J. Clin. Oncol. 18, 995\u20131003 (2000).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd1933_CR18","first-page":"490a","volume":"92","author":"S O'Brien","year":"1998","unstructured":"O'Brien, S. et al. Compound 506 has activity in mature lymphoid leukemia. Blood 92, 490a (1998).","journal-title":"Blood"},{"key":"BFnrd1933_CR19","unstructured":"IMS Health Analysis, IMS MIDAS Quantum, MAT (June 2005) and IMS Oncology Analyzer."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrd1933.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd1933","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd1933.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:51:07Z","timestamp":1684468267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd1933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["BFnrd1933"],"URL":"https:\/\/doi.org\/10.1038\/nrd1933","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}